Rivulet Media (RIVU) 10-Q 12 Dec 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Oct. 31, 2019	Nov. 21, 2019
Document And Entity Information
Entity Registrant Name	Bio-Matrix Scientific Group, Inc.
Entity Central Index Key	0001079282
Document Type	10-Q
Document Period End Date	Oct. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Is Entity's Reporting Status Current?	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		15,616,865,172
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019
Entity Small Business?	true
Entity Emerging Growth Company?	false

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
CURRENT ASSETS
Cash	$ 978	$ 1,722
Accrued Interest Receivable	6,884	6,884
Total Current Assets	7,862	8,606
OTHER ASSETS
Investment Securities	32,980	48,199
Total Other Assets	32,980	48,199
TOTAL ASSETS	40,842	56,805
CURRENT LIABILITIES
Accounts Payable		295
Notes Payable	74,592	67,392
Notes Payable , Related Parties	10,100	0
Accrued Interest	61	0
Accrued Interest, Related Parties	194	0
Total Current Liabilities	84,946	67,687
Total Liabilities	84,946	67,687
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2025760  issues and outstanding as of October 31, 2019 and July 31, 2019	202	202
Common Stock ($.0001 par value) 16,000,000,000 shares authorized and 15,616,865,172  issued and outstanding as of October 31, 2019 and July 31,	1,561,687	1,561,687
Additional Paid in capital	10	10
Contributed Capital	630	630
Accumulated Deficit	(1,606,705)	(1,573,483)
Total Stockholders' Deficit	(44,104)	(10,882)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	40,842	56,805
Series AA Preferred
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2025760  issues and outstanding as of October 31, 2019 and July 31, 2019
Series AAA Preferred
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2025760  issues and outstanding as of October 31, 2019 and July 31, 2019
Series B Preferred
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2025760  issues and outstanding as of October 31, 2019 and July 31, 2019	72	72
Nonvoting Convertible Preferred
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 20,000,000 shares authorized; 2025760  issues and outstanding as of October 31, 2019 and July 31, 2019

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Oct. 31, 2019	Jul. 31, 2019
Common stock, par value (in dollars per share)	$ .0001	$ 0.0001
Common stock, shares authorized	16,000,000,000	16,000,000,000
Common stock, shares issued	15,616,865,172	15,616,865,172
Common stock, shares outstanding	15,616,865,172	15,616,865,172
Preferred stock, par value	$ .0001	$ .0001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	2,025,760	2,025,760
Preferred stock, shares outstanding	2,025,760	2,025,760
Series AA Preferred
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series AAA Preferred
Preferred stock, par value	$ .0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	724,198
Preferred stock, shares outstanding	724,198	724,198
Nonvoting Convertible Preferred
Preferred stock, par value	$ 1	$ 1
Preferred stock, shares authorized	200,000	200,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited)	3 Months Ended
	Oct. 31, 2019USD ($)$ / sharesshares
Income Statement [Abstract]
REVENUES	$ 9,393
COST AND EXPENSES
General and Administrative	9,023
Consulting and Professional Fees	18,119
Total Costs and Expenses	27,142
OPERATING LOSS	(17,749)
OTHER INCOME & (EXPENSES)
Change in Fair Value of Investment Securities	(15,219)
Interest Expense	(61)
Interest Expense, Related Parties	(194)
Total Other Income & (Expense)	(15,474)
NET INCOME (LOSS)	(33,222)
NET INCOME (LOSS) available to common shareholders	$ (33,222)
BASIC AND FULLY DILUTED EARNINGS (LOSS) | $ / shares	$ 0
Weighted average number of shares outstanding | shares	15,616,865,172

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - 3 months ended Oct. 31, 2019 - USD ($)	Series AA Preferred	Series B Preferred	Series AAA Preferred	Preferred Stock	Common Stock	Nonvoting Convertible Preferred	Additional Paid-In Capital	Accumulated Deficit	Contributed Capital	Total
Beginning balance, Shares at Jul. 31, 2019	0	724,198	0	2,025,760	15,616,865,172	0
Beginning balance, Amount at Jul. 31, 2019				$ 202	$ 1,561,687		$ 10	$ (1,573,483)	$ 630	$ (10,882)
Net Loss								(33,222)		(33,222)
Ending balance, Shares at Oct. 31, 2019	0	724,198	0	2,025,760	15,616,865,172	0
Ending balance, Amount at Oct. 31, 2019				$ 202	$ 1,561,687		$ 10	$ (1,606,705)	$ 630	$ 44,104

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Cash Flows (Unaudited)	3 Months Ended
	Oct. 31, 2019USD ($)
Statement of Cash Flows [Abstract]
Net Income (loss)	$ (33,222)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Decrease in Accounts Payable	(295)
Increase in Accrued Expenses	254
Change in Fair Value of Investment Securities	(15,219)
Net Cash Provided by (Used in) Operating Activities	(18,044)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase in Notes Payable	17,300
Net Cash Provided by (Used in) Financing Activities	17,300
Net Increase( Decrease) in Cash	(744)
Cash at Beginning of Period	1,722
Cash at End of Period	$ 978

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Bio-Matrix Scientific Group, Inc. (“Company”) was organized October 6, 1998, under the laws of the State of Delaware as Tasco International, Inc. From October 6, 1998 to June 3, 2006 its activities have been limited to capital formation, organization, and development of its business plan to provide production of visual content and other digital media, including still media, 360-degree images, video, animation and audio for the Internet. On July 3, 2006 the Company abandoned its efforts in the field of digital media production when it acquired 100% of the share capital of Bio-Matrix Scientific Group, Inc., a Nevada corporation, (“BMSG”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by John Lauring. As a result of this transaction, the former stockholder of BMSG held approximately 80% of the voting capital stock of the Company immediately after the transaction. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by BMSG under the purchase method of accounting, and was treated as a recapitalization with BMSG as the acquirer. On July 31, 2019 the Company acquired 100% of the share capital of Pine Hills, Inc. (“Acquisition”), a Wyoming corporation, for consideration consisting of: 8,160,000,000 common shares of the Company issued to Heather Cassady, the sole shareholder of Pine Hills, Inc. (“Pine Hills Shareholder”) The agreement that the sole officer and director of the Company shall resign and the Company shall appoint the nominees of the Pine Hills Shareholder to serve as Chairman of the Company, Chief Executive Officer of the Company, Chief Financial Officer of the Company, Secretary of the Company and Treasurer of the Company. The cancellation by the Company of all outstanding shares of Series AA and Series AA Preferred stock of the Company. Upon completion of the Acquisition, the Pine Hills shareholder owned approximately 54% of the voting capital stock of the Company immediately after the transaction. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by Pine Hills, Inc. and was treated as a recapitalization with Pine Hills Inc. as the acquirer. The Company, through its wholly owned subsidiary Pine Hills, Inc., provides services consisting of data storage and the archiving of corporate documents. 6 A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a July 31 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, Inc., a Delaware corporation and Pine Hills Inc., a Wyoming corporation and 100% owned subsidiary. C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. D. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. E. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of October 31, 2019 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. 7 F. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of October 31, 2019 H. INVESTMENT SECURITIES The Company measures equity investments (except those accounted for under the equity method and those that result in consolidation of the investee) at fair value and recognizes any changes in fair value in net income. I. REVENUE RECOGNITION During the period beginning with inception (February 7, 2019) and ending October 31, 2019 the Company recognized revenue in accordance with ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In order to achieve the core principle of ASC 606, the Company applies the following steps with regard to recognition of revenue: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when the Company satisfies a performance obligation. During the quarter ending October 31, 2019 the Company recognized revenue of $9,023. Revenue was generated by the providing of long term data storage services and data backup services to customers. Revenues from contracts with customers are recognized when: (i) persuasive evidence of an arrangement exists; (ii) services have been completed; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the invoicing of services. Payment is typically due immediately upon submission of invoice. Invoices are submitted once all performance obligation have been met by the Company. Performance obligations are considered to have been met by the Company once all services contracted to be rendered have been provided. The Company has not provided warranties of any kind to customers during the quarter ended October 31, 2019. The Company has determined that for the quarter ending October 31, 2019 revenues recognized were identically similar in regard to nature, amount, timing, and uncertainty of revenues that disaggregation was not required. Pricing of services during the period was determined by Pine Hill’s Chief Technology Officer based on the officer’s sole determination taking into account factors including level of expertise required to complete the task and time required to complete the task. Performance obligations in regards to Long Term data and document storage are considered completed when all of paper documents are digitized ( if applicable) and an appropriate storage scenario ( including cloud, external hard drives, or offsite servers) for the client’s needs has been identified and implemented. 8 Performance obligations in regards to data backup services are considered completed when an optimum frequency of data archival activities as well as optimal security levels to be utilized by the customer are established in consultation with the Company . All revenue earned during the period was attributable to contracts with customers. The Company determined that all contracts entered into during the period are substantially similar in regard to factors to be considered as per ASC 606-10-50-5. During quarter ended October 31, 2019 all performance obligations required of the Company pursuant to contracts with customers entered into by the Company were completed within the period. During the quarter ended October 31, 2019 all consideration due to the Company pursuant to contracts with customers was paid to the Company within the period. The customer is determined to have control of the services to be provided once services have been completed.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Oct. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2 . RECENT ACCOUNTING PRONOUNCEMENTS In January 2016, the FASB issued Accounting Standards Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 requires that equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) are to be measured at fair value with changes in fair value recognized in net income. The Company has adopted ASU 2016-01 effective the fiscal year ending 2019. This guidance is not expected to have a material impact on the Company’s financial statements. In May 2014, the FASB, in conjunction with the International Accounting Standards Board ("IASB"), issued ASU No. 2014-09, "Revenue from Contracts with Customers" (ASC 606), which supersedes the existing revenue recognition requirements under U.S. GAAP and eliminates industry-specific guidance. The new revenue recognition standard provides a five step analysis of transactions to determine when and how revenue is recognized. The new model requires revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. The Company has adopted ASC 606 since inception ( February 7, 2019). On February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842). The ASU requires organizations that lease assets, referred to as "lessees," to recognize on the consolidated statement of financial position the rights and obligations created by those leases. The ASU also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the consolidated financial statements. The ASU on leases became effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has not adopted the provisions of this ASU. This guidance is not expected to have a material impact on the Company’s financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. This ASU is effective for annual periods beginning after December 15, 2018 and interim periods within those annual periods, with early adoption permitted. We adopted the provisions of this ASU in the fiscal year ended 2019. This guidance is not expected to have a material impact on the Company’s financial statements.

Going Concern

Going Concern	3 Months Ended
	Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated net losses of $1,606,705 during the period from February 7, 2019 (inception) through October 31, 2019. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations and to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Acquisition of Pine Hills, Inc.

Acquisition of Pine Hills, Inc.	3 Months Ended
	Oct. 31, 2019
Notes to Financial Statements
Acquisition of Pine Hills, Inc.	NOTE 4. ACQUISITION OF PINE HILLS, INC. On July 31, 2019 the Company consummated the acquisition of 100% of the outstanding shares of Pine Hills , Inc. for consideration consisting of the following: 8,160,000,000 common shares of the Company issued to Heather Cassady, the sole shareholder of Pine Hills, Inc. (“Pine Hills Shareholder”) The resignation of the sole officer and director of the Company, David R. Koos The appointment of Heather Cassady as Chairman of the Company. The appointment of Timothy Foat to the positions of Chief Executive Officer of the Company, Chief Financial Officer of the Company, Secretary of the Company and Treasurer of the Company. The cancellation by the Company of all outstanding shares of Series AA and Series AA Preferred stock of the Company. The acquisition of Pine Hills, Inc. (“PHI”) was accounted for as a reverse merger in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Under this method of accounting, the Company was treated as the “acquired” company for accounting purposes. This determination was primarily based on PHI’s equity holders having a majority of the voting power of the combined company, PHI. comprising the ongoing operations of the combined entity, PHI comprising a majority of the governing body of the combined company, and senior management selected by the former majority shareholder of PHI comprising the senior management of the combined company. The following assets and liabilities of the Company were recognized in connection with the reverse merger as of July 31, 2019: Assets: Cash: $ 340 Accrued Interest Receivable: $ 6,884 Investment Securities with a Fair Value of $ 48,199 Liabilities: Accounts Payable of $ 295 Notes Payable of $ 67,392 The completion of the reverse merger resulted in the Company recognizing a one time noncash charge of $1,574,225 resulting from the aggregate of: 15, 616,865, 172 Common Shares of the Company recognized in the reverse merger at par value ($0.0001) 2,025,846 Preferred Shares of the Company recognized in the reverse merger at par value ($0.0001) 724,222 of the Series B Preferred Shares of the Company recognized in the reverse merger at par value ($0.0001) a noncashcharge of $12,483 representing the net liabilities recognized in the reverse merger.

Accrued Interest Receivable

Accrued Interest Receivable	3 Months Ended
	Oct. 31, 2019
Notes to Financial Statements
Accrued Interest Receivable	NOTE 5. ACCRUED INTEREST RECEIVABLE Accrued Interest Receivable recognized in the reverse merger consists of $6,884 of interest earned but not received due to the Company by Regen Biopharma, Inc. and recognized in the reverse merger. Accrued Interest Receivable of $6,884 is due at the demand of the Company.

Notes Payable and Notes Payable

Notes Payable and Notes Payable Related Parties	3 Months Ended
	Oct. 31, 2019
Debt Disclosure [Abstract]
Notes Payable and Notes Payable Related Parties	NOTE 6. NOTES PAYABLE AND NOTES PAYABLE RELATED PARTIES Notes Payable as of October 31, 2019 consist of the following: David Koos $ 18,992 Blackbriar Partners $ 48,400 BST Partners $ 7,200 Total $ 74,592 $18,992 due to David Koos bears no interest and is due and payable at the demand of the Holder $48,400 due to Blackbriar Partners bears no interest and is due and payable at the demand of the Holder $1,000 due to BST Partners bears simple interest at 10% per annum. Both principal and accrued interest are due and payable on August 12, 2020 $6,200 due to BST Partners bears simple interest at 10% per annum. Both principal and accrued interest are due and payable on October 8, 2020 Notes Payable to Related Parties as of October 31, 2019 consist of the following: Bostonia Partners, Inc. $ 10,100 $10,000 due to Bostonia Partners, Inc. bears simple interest at 10% per annum. Both principal and accrued interest are due and payable on August 22, 2020 $100 due to Bostonia Partners, Inc. bears simple interest at 10% per annum. Both principal and accrued interest are due and payable on August 29, 2020 Mr. Timothy Foat, Chief Executive Officer of the Company, Chief Financial Officer of the Company, Secretary of the Company and Treasurer of the Company is sole officer and Director of Bostonia Partners, Inc

Shareholder's Equity

Shareholder's Equity	3 Months Ended
	Oct. 31, 2019
Equity [Abstract]
Shareholder's Equity	NOTE 7. SHAREHOLDER’S EQUITY The stockholders' equity section of the Company contains the following classes of capital stock as of October 31, 2019: Preferred stock, $0.0001 par value; 20,000,000 shares authorized: 2,025,760 Preferred Shares, par value $0.0001, issued and outstanding. 11 With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. 0 Series AA Preferred Shares, par value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,0000). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series AA Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. 0 Series AAA Preferred Shares, par value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AAA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AAA Preferred Stock owned by such holder times one hundred thousand (100,0000). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series AAA Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. 724,198 Series B Preferred Shares, Par Value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series B Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times two (2). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series B Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. Non Voting Convertible Preferred Stock, $1.00 Par value, 200,000 shares authorized, 0 shares issued and outstanding Each Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert. “CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P. “PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock. “TRADING DAY” shall mean a day on which the Principal Market shall be open for business. 12 On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Non Voting Convertible Preferred shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. Common stock, $0.0001 par value; 16,000,000,000 shares authorized: 15,616,865,172 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

Related Party Transactions

Related Party Transactions	3 Months Ended
	Oct. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 8. RELATED PARTY TRANSACTIONS During the period commencing from inception and ending October 31, 2019 a company controlled by the Company’s Chief Executive Officer made capital contributions of $630 to the Company. Bostonia Partners, Inc., a company controlled by the Company’s Chief Executive Officer, has loaned the Company an aggregate principal amount of $10,100 during the quarter ended October 31, 2019 ( Note 6) The Company utilizes office space free of charge provided by a company controlled by the Company’s Chief Executive Officer.

Investment Securities

Investment Securities	3 Months Ended
	Oct. 31, 2019
Notes to Financial Statements
Investment Securities	NOTE 9. INVESTMENT SECURITIES On July 31, 2019 the Company recognized 66,667 of the common shares of Entest Group, Inc. acquired in the reverse merger. On July 31, 2019 the Company recognized 29,076,665 of the common shares of Regen Biopharma, Inc. acquired in the reverse merger. On July 31, 2019 the Company recognized 2,907,665 of the Series A Preferred shares of Regen Biopharma, Inc. acquired in the reverse merger. On July 31, 2019 the Company recognized 4,411 of the common shares of Zander Therapeutics, Inc. acquired in the reverse merger. On July 31, 2019 the Company recognized 5,000 of the Series M Preferred Shares of Zander acquired in the reverse merger On July 31, 2019 the Company recognized 8,333 of the Preferred Series B shares of of Entest Group, Inc. acquired in the reverse merger. 13 The abovementioned constitute the Company’s sole investment securities as of October 31, 2019. As of October 31, 2019 66,667 Common Shares of Entest Group, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 1,133 $ 1,426 $ 293 $ 293 29,076,665 Common Shares of Regen Biopharma, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 17,446 $ 23,261 $ 5,815 $ 5,815 290,766 Series A Preferred Shares of Regen Biopharma, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 29,076 8,141 $ (20,935 ) $ (20,935 ) 4411 Common Shares of Zander Therapeutics, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 254 $ 71 $ (184 ) $ (184 ) 5000 Series M Preferred Shares of Zander Therapeutics, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 289 $ 80 $ (209 ) $ (209 ) 8,333 Series B Preferred Shares of Entest Group, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 0 $ 0 $ 0 $ 0

Subsequent Events

Subsequent Events	3 Months Ended
	Oct. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 10: SUBSEQUENT EVENTS Management has evaluated subsequent events through the date of issuance noting no material subsequent events to report.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Oct. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a July 31 year-end.
PRINCIPLES OF CONSOLIDATION	B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, Inc., a Delaware corporation and Pine Hills Inc., a Wyoming corporation and 100% owned subsidiary.
CASH EQUIVALENTS	C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
FAIR VALUE OF FINANCIAL INSTRUMENTS	D. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
INCOME TAXES	E. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of October 31, 2019 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.
BASIC EARNING (LOSS) PER SHARE	F. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of October 31, 2019
INVESTMENT SECURITIES	H. INVESTMENT SECURITIES The Company measures equity investments (except those accounted for under the equity method and those that result in consolidation of the investee) at fair value and recognizes any changes in fair value in net income.
REVENUE RECOGNITION	I. REVENUE RECOGNITION During the period beginning with inception (February 7, 2019) and ending October 31, 2019 the Company recognized revenue in accordance with ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In order to achieve the core principle of ASC 606, the Company applies the following steps with regard to recognition of revenue:

Acquisition of Pine Hills, In_2

Acquisition of Pine Hills, Inc. (Tables)	3 Months Ended
	Oct. 31, 2019
Notes to Financial Statements
Assets and Liabilities of the Company	Assets: Cash: $ 340 Accrued Interest Receivable: $ 6,884 Investment Securities with a Fair Value of $ 48,199 Liabilities: Accounts Payable of $ 295 Notes Payable of $ 67,392

Notes Payable and Notes Payab_2

Notes Payable and Notes Payable Related Parties (Tables)	3 Months Ended
	Oct. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	David Koos $ 18,992 Blackbriar Partners $ 48,400 BST Partners $ 7,200 Total $ 74,592
Notes Payable to Related Parties	Bostonia Partners, Inc. $ 10,100

Investment Securities (Tables)

Investment Securities (Tables)	3 Months Ended
	Oct. 31, 2019
Notes to Financial Statements
Marketable Securities	66,667 Common Shares of Entest Group, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 1,133 $ 1,426 $ 293 $ 293 29,076,665 Common Shares of Regen Biopharma, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 17,446 $ 23,261 $ 5,815 $ 5,815 290,766 Series A Preferred Shares of Regen Biopharma, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 29,076 8,141 $ (20,935 ) $ (20,935 ) 4411 Common Shares of Zander Therapeutics, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 254 $ 71 $ (184 ) $ (184 ) 5000 Series M Preferred Shares of Zander Therapeutics, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 289 $ 80 $ (209 ) $ (209 ) 8,333 Series B Preferred Shares of Entest Group, Inc. Basis Fair Value Change in Fair Value for the Quarter ended October 31 2019 Change in Fair Value for the period from Inception (2/7/1019) to 10/31/2019 $ 0 $ 0 $ 0 $ 0

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Date of Incorporation	Oct. 6, 1998
Common shares issued	15,616,865,172	15,616,865,172
Revenue	$ 9,393
Heather Cassady
Common shares issued		8,160,000,000
Pine Hills, Inc.
Ownership		54.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Deficit	$ 1,606,705	$ 1,573,483

Acquisition of Pine Hills, In_3

Acquisition of Pine Hills, Inc. - Assets and Liabilities of the Company (Details) - USD ($)	3 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Assets:
Cash	$ 340
Accrued Interest Receivable	6,884	$ 6,884
Investment Securities with a Fair Value of	32,980	48,199
Liabilities:
Accounts Payable of		295
Notes Payable	$ 74,592	$ 67,392

Acquisition of Pine Hills, In_4

Acquisition of Pine Hills, Inc. (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Reverse Merger One Time Noncash Charge	$ 12,483
Common stock, par value (in dollars per share)	$ .0001	$ 0.0001
Common stock, shares outstanding	15,616,865,172	15,616,865,172
Preferred stock, par value	$ .0001	$ .0001
Preferred stock, shares outstanding	2,025,760	2,025,760
Series B Preferred
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares outstanding	724,198	724,198

Accrued Interest Receivable (De

Accrued Interest Receivable (Details Narrative) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Notes to Financial Statements
Accrued Interest Receivable	$ 6,884	$ 6,884

Notes Payable and Notes Payab_3

Notes Payable and Notes Payable Related Parties - Notes Payable (Details) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Total	$ 74,592	$ 67,392
David Koos
Total	18,992
Blackbriar Partners
Total	48,400
BST Partners
Total	$ 7,200

Notes Payable and Notes Payab_4

Notes Payable and Notes Payable Related Parties - Notes Payable to Related Parties (Details) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Notes Payable , Related Parties	$ 10,100	$ 0
Bostonia Partners, Inc.
Notes Payable , Related Parties	$ 10,100

Notes Payable and Notes Payab_5

Notes Payable and Notes Payable Related Parties (Details Narrative) - USD ($)	3 Months Ended
	Oct. 31, 2019	Jul. 31, 2019
Total	$ 74,592	$ 67,392
Notes Payable , Related Parties	10,100	$ 0
BST Partners | Note 1
Total	$ 1,000
Accrued Interest	10.00%
Maturity Date	Aug. 12, 2020
BST Partners | Note 2
Total	$ 6,200
Accrued Interest	10.00%
Maturity Date	Oct. 8, 2020
Bostonia Partners, Inc.
Notes Payable , Related Parties	$ 10,100
Bostonia Partners, Inc. | Note 1
Accrued Interest	10.00%
Maturity Date	Aug. 22, 2020
Notes Payable , Related Parties	$ 10,000
Bostonia Partners, Inc. | Note 2
Accrued Interest	10.00%
Maturity Date	Aug. 29, 2020
Notes Payable , Related Parties	$ 100
David Koos
Total	18,992
Blackbriar Partners
Total	$ 48,400

Shareholder's Equity (Details N

Shareholder's Equity (Details Narrative) - $ / shares	Oct. 31, 2019	Jul. 31, 2019
Preferred stock, par value	$ .0001	$ .0001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	2,025,760	2,025,760
Preferred stock, shares outstanding	2,025,760	2,025,760
Common stock, par value (in dollars per share)	$ .0001	$ 0.0001
Common stock, shares authorized	16,000,000,000	16,000,000,000
Common stock, shares issued	15,616,865,172	15,616,865,172
Common stock, shares outstanding	15,616,865,172	15,616,865,172
Series AA Preferred
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	724,198
Preferred stock, shares outstanding	724,198	724,198
Series AAA Preferred
Preferred stock, par value	$ .0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Nonvoting Convertible Preferred
Preferred stock, par value	$ 1	$ 1
Preferred stock, shares authorized	200,000	200,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Oct. 31, 2019	Jul. 31, 2019
Contributed Capital	$ 630	$ 630
Notes Payable , Related Parties	10,100	$ 0
Bostonia Partners, Inc.
Notes Payable , Related Parties	$ 10,100

Investment Securities - Marketa

Investment Securities - Marketable Securities (Details)	3 Months Ended
	Oct. 31, 2019USD ($)shares
Entest Group, Inc. | Common Stock
Shares held | shares	66,667
Investment Securities, Basis	$ 1,133
Investment Securities, Fair Value	1,426
Change in Fair Value	293
Change in Fair Value From Inception	$ 293
Entest Group, Inc. | Series B Preferred
Shares held | shares	8,333
Investment Securities, Basis	$ 0
Investment Securities, Fair Value	0
Change in Fair Value	0
Change in Fair Value From Inception	$ 0
Regen Biopharma, Inc. | Common Stock
Shares held | shares	29,076,665
Investment Securities, Basis	$ 17,446
Investment Securities, Fair Value	23,261
Change in Fair Value	5,815
Change in Fair Value From Inception	$ 5,815
Regen Biopharma, Inc. | Series A Preferred
Shares held | shares	290,766
Investment Securities, Basis	$ 29,076
Investment Securities, Fair Value	8,141
Change in Fair Value	(20,935)
Change in Fair Value From Inception	$ (20,935)
Zander Therapeutics, Inc. | Common Stock
Shares held | shares	4,411
Investment Securities, Basis	$ 254
Investment Securities, Fair Value	71
Change in Fair Value	(184)
Change in Fair Value From Inception	$ (184)
Zander Therapeutics, Inc. | Series M Preferred
Shares held | shares	5,000
Investment Securities, Basis	$ 289
Investment Securities, Fair Value	80
Change in Fair Value	(209)
Change in Fair Value From Inception	$ (209)

Investment Securities (Details

Investment Securities (Details Narrative)	Oct. 31, 2019shares
Entest Group, Inc. | Common Stock
Shares held	66,667
Entest Group, Inc. | Series B Preferred
Shares held	8,333
Regen Biopharma, Inc. | Common Stock
Shares held	29,076,665
Regen Biopharma, Inc. | Series A Preferred
Shares held	290,766
Zander Therapeutics, Inc. | Common Stock
Shares held	4,411
Zander Therapeutics, Inc. | Series M Preferred
Shares held	5,000